As part of its growth strategy in the Easter European Market, Tabuk had received registration approvals for two cardiovascular products; Simvastatin & Atorvastatin. Atorvastatin is one of the leading cholesterol lowering agents in the Hungarian market.
At least three additional registration approvals are expected before the end of 2008.